|
| 36321730 | The best and worst of times in therapy development for myasthenia gravis. | Muscle Nerve | 2023 |
| 37965295 | Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma. | Mol Ther Oncolytics | 2023 |
| 37555492 | Improving the efficiency of clinical trials in multiple sclerosis. | Mult Scler | 2023 |
| 37745647 | Quantitative sleep electroencephalogram and cognitive performance in Parkinson's disease with and without rapid eye movement sleep behavior disorder. | Front Neurol | 2023 |
| 37586313 | Randomized controlled trial of the behavioral intervention for physical activity in multiple sclerosis project: Social cognitive theory variables as mediators. | Mult Scler Relat Disord | 2023 |
| 37515491 | Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis. | J Comp Eff Res | 2023 |
| 37479372 | Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. | Lancet Neurol | 2023 |
| 37941523 | Umbilical Cord Milking Versus Delayed Cord Clamping in Infants 28 to 32 Weeks: A Randomized Trial. | Pediatrics | 2023 |
| 37830451 | Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset. | Mult Scler | 2023 |
| 37638552 | Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. | Ann Neurol | 2023 |
| 37221052 | Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. | J Neurol Neurosurg Psychiatry | 2023 |
| 37290970 | Polygenicity of Comorbid Depression in Multiple Sclerosis. | Neurology | 2023 |
| 37119208 | The impact of relapse definition and measures of durability on MS clinical trial outcomes. | Mult Scler | 2023 |
| 37184850 | Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. | JAMA Neurol | 2023 |
| 37282545 | Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. | Mult Scler | 2023 |
| 37077172 | Imposter clinical trials or answering questions with observational data. | Mult Scler | 2023 |
| 37076302 | Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. | Neurology | 2023 |
| 37173129 | Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis. | J Neurol Neurosurg Psychiatry | 2023 |
| 37306560 | Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis. | Eur J Neurol | 2023 |
| 37139460 | Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial. | Mult Scler J Exp Transl Clin | 2023 |
| 37101754 | Severity and worsening of fatigue among individuals with multiple sclerosis. | Mult Scler J Exp Transl Clin | 2023 |
| 37072219 | Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset. | Neurology | 2023 |
| 37401775 | Effects of a More Selective Arteriovenous Fistula Strategy on Vascular Access Outcomes. | J Am Soc Nephrol | 2023 |
| 37131624 | Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma. | bioRxiv | 2023 |
| 37066921 | Quantitative Sleep Electroencephalogram in Parkinson's Disease: A Case-Control Study. | J Parkinsons Dis | 2023 |
| 36881147 | Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study. | J Neurol | 2023 |
| 36852731 | Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD). | Ann Clin Transl Neurol | 2023 |
| 36649911 | Diet, Physical Activity, and Stress Among Wheelchair Users With Multiple Sclerosis: Examining Individual and Co-Occurring Behavioral Risk Factors. | Arch Phys Med Rehabil | 2023 |
| 36779059 | Attitudes of people with multiple sclerosis toward brain donation. | Front Neurol | 2023 |
| 36843446 | Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project. | Mult Scler | 2023 |
| 36436069 | Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis. | J Neurol | 2023 |
| 36535606 | Randomized controlled trial of the behavioral intervention for increasing physical activity in multiple sclerosis project: Secondary, patient-reported outcomes. | Contemp Clin Trials | 2023 |
| 36462470 | The nine hole peg test as an outcome measure in progressive MS trials. | Mult Scler Relat Disord | 2023 |
| 36933030 | Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis. | J Neurol | 2023 |
| 36931078 | Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. | Mult Scler Relat Disord | 2023 |
| 36324261 | Impact of the COVID-19 pandemic on patients with myasthenia gravis: A survey of the Myasthenia Gravis Foundation of America MG patient registry. | Muscle Nerve | 2023 |
| 34304609 | MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. | Mult Scler | 2022 |
| 35839562 | COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes. | Mult Scler Relat Disord | 2022 |
| 35733947 | Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple Sclerosis. | Neurol Clin Pract | 2022 |
| 35673964 | One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry. | Muscle Nerve | 2022 |
| 35836272 | Clinical risk factors for admission with Pseudomonas and multidrug-resistant Pseudomonas community-acquired pneumonia. | Antimicrob Resist Infect Control | 2022 |
| 35373638 | Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. | Mult Scler | 2022 |
| 35398713 | Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies. | Mult Scler Relat Disord | 2022 |
| 35342087 | Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease. | J Alzheimers Dis | 2022 |
| 35793732 | Satisfaction with modes of telemedicine delivery during COVID-19: A randomized, single-blind, parallel group, noninferiority trial. | Am J Med Sci | 2022 |
| 35699291 | Absolute quantification of plasma mitochondrial DNA by droplet digital PCR marks COVID-19 severity over time during intensive care unit admissions. | Am J Physiol Lung Cell Mol Physiol | 2022 |
| 35367873 | The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. | Mult Scler Relat Disord | 2022 |
| 35570237 | The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. | J Neurol | 2022 |
| 35531965 | The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis. | Mult Scler | 2022 |
| 35634012 | Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis. | Mult Scler J Exp Transl Clin | 2022 |